DOI: https://doi.org/10.21203/rs.3.rs-827910/v1
Objectives: We had a patient with COVID-19 encephalitis who demonstrated striking brain atrophy on 3 MRI scans 60 days apart. We aimed to quantify the volume loss and brain atrophy. This is the first report that quantifies brain atrophy with COVID encephalitis.
Methods: A 75 year old partially vaccinated man with COVID encephalitis underwent 3 serial MRI scans. Manual volumetry using PACS software was used to average and quantify brain atrophy between the three scans.
Results: In 60 days, our patient had approximately 11.52 % (117 ml) of forebrain atrophy, which corresponded to 78 years of accelerated aging. Cerebellar atrophy of 6.2% (7.7 cc) was also noted.
Discussion: We have demonstrated striking brain atrophy with COVID encephalitis. Brain involvement and atrophy or connectome disruptions might contribute to post COVID cognitive impairment. Serial MRI scans after COVID-19 and volumetric analysis may detect post COVID brain atrophy as a cause of cognitive dysfunction.
A 75-year-old healthy man came back from his farm and fell unconscious onto his bed for a few minutes. He had been partially vaccinated with the ChAdOx1 (Astra-Zeneca) vaccine 2 months earlier. On evaluation, he was febrile (38.5oC) akinetic, mute, and rigid. Serum CPK levels were normal. Nasopharyngeal swab for SARS-CoV2-RT-PCR was positive. Routine workup for other causes of fever were negative.
MRI brain showed a right frontal FLAIR hyperintensity with overlying leptomeningeal contrast enhancement. CSF showed 90 cells (L90 N10) with high protein (164mg/dl). A pan-encephalitic PCR panel was negative. Serum inflammatory markers and troponin were elevated. CT Thorax was normal. COVID encephalitis was diagnosed and he was started on Remdesivir, Dexamethasone, and levodopa 800mg/day. He improved slightly and was extubated on day 7. On day 26 a repeat MRI showed striking brain atrophy.
Over the next 1 month, he improved to a modified Rankin score of 4 (moderate disability, unable to walk without assistance and needing full time care) but remained apathetic, mute and rigid with a requirement of up to 600 mg of Levodopa per day. A third MRI was performed on day 60.
Due to COVID-19 limitations, only partial MRI studies could be obtained in our patient. As FLAIR sequences had been performed consistently in all studies, axial FLAIR images were used for brain volume analysis instead of T1 weighted images. Corresponding sections (at least axial 3 sequences each of the fore-brain and cerebellum, at 5 mm thickness) were used for volume calculation. Using our in-built PACS software (InstaRISPACS version 5.0), manual contouring was performed and auto-calculation of area was obtained (brain region volume minus ventricular volume). The average of 3 measurements was taken and the absolute and percentage of decrease in brain volumes were calculated between both sequences.
Recalculating this equation, 1% of forebrain volume is equivalent to 10.2 cc (ml) of forebrain, the loss of which is proportionate to ~ 6.8 years of aging (approximately 6 years and 10 months of aging). By day 60, our patients had a calculated percentage of forebrain atrophy of approximately 11.5 % (117 ml) which corresponded to 78 years of accelerated aging.3 Cerebellar atrophy of 6.2% (7.7 cc) was also noted.
Although many neurological complications and MRI changes of COVID-19 have been described, few have looked at COVID-19 induced brain atrophy. One study noted that >70% of critically ill patients developed an increase in ventricular size (a surrogate of brain atrophy), and linked it to hypoxia or a cytokine storm.6 Olfactory bulb atrophy and optic nerve/ tract hyperintensities (35%) are also described in COVID-19. As there is a high expression of ACE 2 and TMPRSS2 proteases receptors in the olfactory epithelium, rapid invasion of the brain occurs via this route, followed by widespread brain dissemination.
Table 1. Quantification of human fore-brain and cerebellar cell loss; Generalized as well as the estimated brain elements lost per unit time in our case quantified.1,3,5,7
Parameters |
Normative number
|
Normal aging (0.15%)- Loss per year |
1% Neuronal loss |
11.5% Neuronal loss |
Cells in the brain Cerebrum (100%) |
16 Billion (19%)
|
≈31 million 85,000 per day 3541 per hour 60 per minute 1 per second |
160 Million 1 million per day 41,000 per hour 700 per minute 11 per second |
1.84 Billion in 60 days 30 million per day 1.25 million per hour 20,000 per minute 350 per second |
Cerebellum |
69 Billion (71%) |
0.1 Billion |
0.69 Billion |
2.9 Billion |
Non-neuronal cells |
85 Billion |
|
|
|
Volume Mass Cerebrum Cerebellum |
1020 cc 1508 gms 1233 gms 154 gm |
1.53 cc 2.26 gms 1.85 gms 0.23 gms |
10.2 cc 15 gms 12.3 gms 1.54 gm |
117 ml 173 gms 135 gms 9.5 gms |
Myelinated fibers in the human forebrain |
135 000 km |
20,250 Km |
1349 km
|
15513 km |
Synapses in the human forebrain. |
157 Trillion |
0.23 Trillion |
1.56 Trillion
|
18 Trillion |
Aging |
|
Normal |
Accelerated by 6 years and 10 months |
Accelerated by 78 years |
Conflict of interest- None
All necessary patient consent has been obtained
Ethics committee waiver has been obtained as it is a single case report